12.8

Sell/Above-Average Risk - Price 6.31 on March 5
by Zacks Research

This specialty pharmaceutical firm acquires, develops, and commercializes preit scription drugs used to treat a variety of gastrointestinal diseases. It suffered a major setback in December when the FDA granted approval to three generic versions of ... Colazal ... a significant contributor to [its] top and bottom lines. As such, we expect significant declines in both revenues and earnings [in 2008]. While new-product launches and new indications for Xifaxan should support a recovery in revenues in '09, we don't expect earnings to recover prior to '10. Target: 5. Market-cap: $300 million.

Salix Pharma (SLXP) was downgraded by Piper Jaffray from neutral to sell.

growing revenues low stock price

9/6/07 Stocks with Abnormal Put volume.
Power Rating (3)

I expect takeover here. Probably by Biogen. But buying based on cheapness, good growth, overreaction to competitive threat. 3 product label expansions/new approvals in '06. Solid growth, profits.